|Bid||18.11 x 800|
|Ask||45.27 x 800|
|Day's Range||43.92 - 45.36|
|52 Week Range||34.43 - 66.00|
|Beta (5Y Monthly)||1.24|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2022 - Nov 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||71.92|
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2022.
Intra-Cellular (ITCI) delivered earnings and revenue surprises of -16.46% and 12.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Total revenues for the second quarter 2022 were $55.6 million, compared to $20.0 million for the same period in 2021, representing a 178% increase CAPLYTA net product revenues for the second quarter 2022 were $55.1 million, representing a 190% increase over the same period in 2021 and a 58% increase over the first quarter 2022 Second quarter 2022 CAPLYTA new and total prescriptions increased 225% and 191%, respectively, versus the same period in 2021 Second quarter 2022 CAPLYTA new and total pre